GLP-1 Receptor Agonists in Inflammatory Bowel Disease: Mechanisms and Outcomes
Glucagon-like peptide-1 receptor agonists, originally approved for type 2 diabetes and obesity, are increasingly examined for their potential impact on inflammatory bowel disease, including Crohn’s disease and ulcerative colitis, as … Read More